<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC5644647/results/search/test_trace/results.xml">
  <result pre="to an acquired immunodeficiency syndrome. A transient initial state of" exact="infection" post="is followed by a long latent stage with low"/>
  <result pre="terminal stage, both viruses can cause severe immunosuppression. Thus, FIV" exact="infection" post="in cats has become an important natural model for"/>
  <result pre="cats has become an important natural model for studying HIV" exact="infection" post="in humans, especially for evaluation of antiviral compounds. Of"/>
  <result pre="of FIV to many RT-targeted antiviral compounds used in the" exact="treatment" post="of HIV-infected patients. Thus, the aim of this article"/>
  <result pre="is to provide an up-to-date review of studies on antiviral" exact="treatment" post="of FIV, focusing on commercially available compounds for human"/>
  <result pre="available compounds for human or animal use. FIV antiviral compounds" exact="treatment" post="therapy 1. Introduction FIV can induce immunosuppression, which predisposes"/>
  <result pre="[1,2,3]. The most important strategy for managing FIV-infected cats is" exact="treatment" post="of secondary infections. In cats with recurrent infections despite"/>
  <result pre="infections. In cats with recurrent infections despite aggressive management, additional" exact="treatment" post="with antiviral drugs (e.g., plerixafor and/or zidovudine) can be"/>
  <result pre="such as neurologic abnormalities or stomatitis; in these cases, antiviral" exact="treatment" post="(e.g., with zidovudine) is also an option. Antiviral compounds"/>
  <result pre="[4,5]. This review covers the most common drugs used for" exact="treatment" post="of FIV infection (Table A1): reverse transcriptase inhibitors (RTIs),"/>
  <result pre="covers the most common drugs used for treatment of FIV" exact="infection" post="(Table A1): reverse transcriptase inhibitors (RTIs), which inhibit the"/>
  <result pre="against HIV [12] and became the first drug approved for" exact="treatment" post="of HIV infection [13]. The anti-FIV activity of zidovudine"/>
  <result pre="and became the first drug approved for treatment of HIV" exact="infection" post="[13]. The anti-FIV activity of zidovudine has been assessed"/>
  <result pre="marrow suppression. Regular blood cell counts are necessary during zidovudine" exact="treatment" post="because non-regenerative anemia is a common side effect [28]."/>
  <result pre="well. The hematocrit can decline within three weeks of initiating" exact="treatment" post="to approximately 50% of baseline but increases afterwards in"/>
  <result pre="of treatment. If the hematocrit drops below 20%, discontinuation of" exact="treatment" post="is recommended, and anemia usually resolves within a few"/>
  <result pre="is another drug effective against HIV. It was approved for" exact="treatment" post="of HIV infection in 1994, but in recent years"/>
  <result pre="effective against HIV. It was approved for treatment of HIV" exact="infection" post="in 1994, but in recent years has been replaced"/>
  <result pre="but in recent years has been replaced in most multi-drug" exact="treatment" post="protocols by compounds with fewer side effects [30,31,32,33,34]. Stavudine"/>
  <result pre="States, it was the second drug to be approved for" exact="treatment" post="of HIV and has been on the market since"/>
  <result pre="replication was significantly suppressed in animals treated with didanosine, but" exact="treatment" post="contributed to the development of antiretroviral toxic neuropathy [39]."/>
  <result pre="with a high-dose zidovudine/lamivudine combination, which protected some cats from" exact="infection" post="when treatment was started before virus inoculation. However, zidovudine/lamivudine"/>
  <result pre="high-dose zidovudine/lamivudine combination, which protected some cats from infection when" exact="treatment" post="was started before virus inoculation. However, zidovudine/lamivudine treatment showed"/>
  <result pre="infection when treatment was started before virus inoculation. However, zidovudine/lamivudine" exact="treatment" post="showed no anti-FIV activity in chronically infected cats. Severe"/>
  <result pre="observed in some of the cats with this high-dose dual-drug" exact="treatment" post="[41]. Thus, high-dose lamivudine treatment alone, or in combination"/>
  <result pre="cats with this high-dose dual-drug treatment [41]. Thus, high-dose lamivudine" exact="treatment" post="alone, or in combination with zidovudine, is not recommended"/>
  <result pre="available as an oral formulation (bis-POM PMEA) approved for the" exact="treatment" post="of chronic hepatitis B. Adefovir belongs to the acyclic"/>
  <result pre="trial and the side effects, adefovir cannot be recommended for" exact="treatment" post="of FIV-infected cats. 3.2. Tenofovir Currently, the only approved"/>
  <result pre="cats. 3.2. Tenofovir Currently, the only approved NtARTi for the" exact="treatment" post="of HIV infection is tenofovir disoproxil fumarate (TDF), the"/>
  <result pre="Currently, the only approved NtARTi for the treatment of HIV" exact="infection" post="is tenofovir disoproxil fumarate (TDF), the prodrug of tenofovir"/>
  <result pre="been used in veterinary medicine. A major breakthrough in the" exact="treatment" post="of FIV would be the discovery of more NNRTIs"/>
  <result pre="has been used as an antitrypanosomal agent and for the" exact="treatment" post="of some tumors, such as prostate cancer [58]. It"/>
  <result pre="retroviruses and has also been used in humans with HIV" exact="infection" post="[59]. Suramin inhibits RT by interacting with the template-primer"/>
  <result pre="and RNA viruses, including retroviruses. It is FDA-approved for the" exact="treatment" post="of HIV-associated cytomegalo and herpes simplex virus infections in"/>
  <result pre="on megakaryocytes, resulting in thrombocytopenia and hemorrhage. With prolonged ribavirin" exact="treatment" post="or at higher doses, the production of erythrocytes and"/>
  <result pre="essential co-receptors for HIV as well as for FIV during" exact="infection" post="of CD4+ lymphocytes [79,80]. By binding to CXCR4, bicyclams"/>
  <result pre="FIV in vitro [82]. In a placebo-controlled double-blinded clinical trial," exact="treatment" post="of naturally FIV-infected cats with plerixafor resulted in a"/>
  <result pre="resistance of FIV isolates to plerixafor did not occur during" exact="treatment" post="[53]. In cats, plerixafor is administered at a dosage"/>
  <result pre="and calcium levels should be performed at regular intervals during" exact="treatment" post="[53]. Further studies investigating the potential of this promising"/>
  <result pre="prevent viral replication. Several PIs have been used for successful" exact="treatment" post="of HIV. Nevertheless, side effects and development of viral"/>
  <result pre="from infected cells and aids in the clearance of virus" exact="infection" post="[97]. Human IFNs have been manufactured by recombinant DNA"/>
  <result pre="many DNA and RNA viruses [98]. There are two common" exact="treatment" post="regimens for use of rHuIFN-α in cats: SC injection"/>
  <result pre="thiat study and therefore it is impossible to conclude whether" exact="treatment" post="with rHuIFN- α had indeed an effect on FIV,"/>
  <result pre="study that investigated the effect of parenteral rFeIFN-ω against FIV" exact="infection" post="in 62 naturally FIV-infected cats (treated with 106 U/kg"/>
  <result pre="intervals, and there were no biochemical abnormalities associated with rFeIFN-ω" exact="treatment" post="[96]. A recent study evaluated the use of oral"/>
  <result pre="evaluated the use of oral administration of rFeIFN-ω for the" exact="treatment" post="of eleven client-owned, naturally FIV-infected cats with clinical signs"/>
  <result pre="eleven client-owned, naturally FIV-infected cats with clinical signs [108]. The" exact="treatment" post="protocol was 105 U/cat PO q 24 h for"/>
  <result pre="10. Conclusions Unfortunately, the efficacy of antiviral compounds for the" exact="treatment" post="of FIV in cats has been generally poor. The"/>
  <result pre="FIV in cats has been generally poor. The duration of" exact="treatment" post="in many clinical trials was relatively short and might"/>
  <result pre="long clinical course. In addition, it is difficult to compare" exact="treatment" post="results of cats infected experimentally and kept under laboratory"/>
  <result pre="feline leukaemia virus among client-owned cats and risk factors for" exact="infection" post="in germanyJ. Feline Med. Surg.20091198599210.1016/j.jfms.2009.05.01919616984 2.AddieD.D.DennisJ.M.TothS.CallananJ.J.ReidS.JarrettO.Long-term impact on a"/>
  <result pre="impact on a closed household of pet cats of natural" exact="infection" post="with feline coronavirus, feline leukaemia virus and feline immunodeficiency"/>
  <result pre="inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the" exact="treatment" post="of HIV infections (AIDS)Adv. Pharmacol.20136731735823886005 11.HorwitzJ.P.ChuaJ.NoelM.Nucleosides. V. The monomesylates"/>
  <result pre="Acad. Sci. USA1985827096710010.1073/pnas.82.20.70962413459 13.EzzellC.Azt given the green light for clinical" exact="treatment" post="of AIDSNature19873264303470603 14.GobertJ.M.RemingtonK.M.ZhuY.Q.NorthT.W.Multiple-drug-resistant mutants of feline immunodeficiency virus selected"/>
  <result pre="and in combination with 3'-azido-3'-deoxythymidineAntimicrob. Agents Chemother.19943886186410.1128/AAC.38.4.8618031060 15.HartmannK.DonathA.KraftW.AZT in the" exact="treatment" post="of feline immunodeficiency virus infection: Part 1Feline Pract1995231621 16.BissetL.R.LutzH.BoniJ.Hofmann-LehmannR.LuthyR.SchupbachJ.Combined"/>
  <result pre="virus (FIV)-induced cytopathic effect: Development of a new method for" exact="screening" post="of anti-FIV substances in vitroAntivir. Res.19921916117210.1016/0166-3542(92)90075-G1332602 25.VahlenkampT.W.De RondeA.BalzariniJ.NaesensL.De ClercqE.van"/>
  <result pre="for acquired immune deficiency syndromeAntimicrob. Agents Chemother.19893391591910.1128/AAC.33.6.9152475068 28.HartmannK.DonathA.KraftW.Azt in the" exact="treatment" post="of feline immunodeficiency virus infection: Part 2Feline Pract.1995231320 29.HartmannK.Feline"/>
  <result pre="virusBiochem. Pharmacol.198736271327182443141 34.MartinJ.C.HitchcockM.J.de ClercqE.PrusoffW.H.Early nucleoside reverse transcriptase inhibitors for the" exact="treatment" post="of HIV: A brief history of stavudine (D4T) and"/>
  <result pre="on 14 July 2015) 41.AraiM.EarlD.D.YamamotoJ.K.Is AZT/3TC therapy effective against FIV" exact="infection" post="or immunopathogenesis?Vet. Immunol. Immunopathol.20028518920410.1016/S0165-2427(01)00426-311943320 42.RavichandranS.VeerasamyR.RamanS.KrishnanP.N.AgravalR.K.An overview on HIV-1 reverse"/>
  <result pre="effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus" exact="infection" post="in Rhesus monkeysAIDS19915212810.1097/00002030-199101000-000032059358 47.HartmannK.DonathA.BeerB.EgberinkH.F.HorzinekM.C.LutzH.Hoffmann-FezerG.ThumI.ThefeldS.Use of two virustatica (AZT, PMEA)"/>
  <result pre="Rhesus monkeysAIDS19915212810.1097/00002030-199101000-000032059358 47.HartmannK.DonathA.BeerB.EgberinkH.F.HorzinekM.C.LutzH.Hoffmann-FezerG.ThumI.ThefeldS.Use of two virustatica (AZT, PMEA) in the" exact="treatment" post="of FIV and of FELV seropositive cats with clinical"/>
  <result pre="clinical symptomsVet. Immunol. Immunopathol.19923516717510.1016/0165-2427(92)90129-E1363008 48.EgberinkH.BorstM.NiphuisH.BalzariniJ.NeuH.SchellekensH.de ClercqE.HorzinekM.KoolenM.Suppression of feline immunodeficiency virus" exact="infection" post="in vivo by 9-(2-phosphonomethoxyethyl)adenineProc. Natl. Acad. Sci. USA1990873087309110.1073/pnas.87.8.30872158102 49.HartmannK.Clinical"/>
  <result pre="subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitorsMol. Pharmacol.20026140040610.1124/mol.61.2.40011809865 58.Garcia-SchurmannJ.M.SchulzeH.HauptG.PastorJ.AllolioB.SengeT.Suramin" exact="treatment" post="in hormone- and chemotherapy-refractory prostate cancerUrology19995353554110.1016/S0090-4295(98)00544-510096380 59.BroderS.YarchoanR.CollinsJ.M.LaneH.C.MarkhamP.D.KleckerR.W.RedfieldR.R.MitsuyaH.HothD.F.GelmannE.et al.Effects of"/>
  <result pre="and chemotherapy-refractory prostate cancerUrology19995353554110.1016/S0090-4295(98)00544-510096380 59.BroderS.YarchoanR.CollinsJ.M.LaneH.C.MarkhamP.D.KleckerR.W.RedfieldR.R.MitsuyaH.HothD.F.GelmannE.et al.Effects of suramin on HTLV-III/LAV" exact="infection" post="presenting as Kaposi’s Sarcoma or AIDS-related complex: Clinical pharmacology"/>
  <result pre="coinfectionLancet200135728028110.1016/S0140-6736(00)03618-711214134 73.PoveyR.C.Effect of orally administered ribavirin on experimental feline calicivirus" exact="infection" post="in catsAm. J. Vet. Res.19783913371341697143 74.WeissR.C.CoxN.R.BoudreauxM.K.Toxicologic effects of ribavirin"/>
  <result pre="virusesJ. Virol.199771899990079371556 78.WillettB.J.HosieM.J.The role of the chemokine receptor CXCR4 in" exact="infection" post="with feline immunodeficiency virusMol. Membr. Biol.199916677210332739 79.WillettB.J.PicardL.HosieM.J.TurnerJ.D.AdemaK.ClaphamP.R.Shared usage of"/>
  <result pre="al.Resolution and prevention of feline immunodeficiency virus-induced neurological deficits by" exact="treatment" post="with the protease inhibitor TL-3J. Virol.2004784525453210.1128/JVI.78.9.4525-4532.200415078933 88.Zeinalipour-LoizidouE.NicolaouC.NicolaidesA.KostrikisL.G.HIV-1 integrase: From"/>
  <result pre="to antiretroviral agentsJ. Virol.2013874322432910.1128/JVI.03208-1223365453 93.BoeschA.CattoriV.RiondB.WilliB.MeliM.L.RentschK.M.HosieM.J.Hofmann-LehmannR.LutzH.Evaluation of the effect of short-term" exact="treatment" post="with the integrase inhibitor raltegravir (Isentress) on the course"/>
  <result pre="retrovirusesViruses2009154557310.3390/v103054521994560 100.ZeidnerN.S.MylesM.H.Mathiason-DuBardC.K.DreitzM.J.MullinsJ.I.HooverE.A.Alpha interferon (2β) in combination with zidovudine for the" exact="treatment" post="of presymptomatic feline leukemia virus-induced immunodeficiency syndromeAntimicrob. Agents Chemother.1990341749175610.1128/AAC.34.9.17492178336"/>
  <result pre="oral natural human interferon alpha) in the management of HIV-1" exact="infection" post="and acquired immune deficiency syndrome (AIDS)East. Afr. Med. J.1990676470"/>
  <result pre="activity of feline ifn-gammaJ. Interferon Cytokine Res.2001211039104610.1089/10799900131720516911798461 106.PedrettiE.PasseriB.AmadoriM.IsolaP.di PedeP.TeleraA.VescoviniR.QuintavallaF.PistelloM.Low-dose interferon-alpha" exact="treatment" post="for feline immunodeficiency virus infectionVet. Immunol. Immunopathol.200610924525410.1016/j.vetimm.2005.08.02016169599 107.De MariK.MaynardL.SanquerA.LebreuxB.EunH.M.Therapeutic"/>
 </snippets>
</snippetsTree>
